Vaccine
Prestige® II
with Havlogen®
Indications

For vaccination of healthy horses 6 months of age or older, as an aid in the control of respiratory disease caused by equine influenza virus (EIV), equine herpesvirus type 1 (EHV-1) and equine herpesvirus type 4 (EHV-4) and as an aid in reduction of virus shedding of EIV and EHV-1. Duration of immunity (DOI) has been shown to be at least 6 months for EIV. Foals nursing immune-dams should be vaccinated when maternal antibody levels will allow active immunization.

The Science of Protected

  • Multiple antigen combinations provides flexibility
  • Formulated to minimize reactions and maximize protection
  • Available in 10-dose vials
  • Also available in convenient, low-volume 1 mL doses in single, prefilled syringes
  • A combination of inactivated, concentrated, adjuvanted, tissue culture origin equine herpesviruses types 1 and 4 (EHV-1 and EHV-4) and equine influenza virus type H3N8 strains (EIV A/Equine 2/ Kentucky/93 American, EIV A/Equine 2/Kentucky/02 American and EIV A/Equine 2/Newmarket/2/93 Eurasian). Intervet serological data suggest influenza cross protection against certain U.S. and European strains, including Kentucky 91, 93, 99, 02, Ohio 03, Newmarket/1/93, Newmarket/2/93, Suffolk 89 and South Africa 03.
  • Exceptional safety profile with the smooth Havlogen® adjuvant
  • Advanced filtration process through the Antigen Purification System (APS)

Science

Resources

Administration

For primary vaccination aseptically administer 1 mL intramuscularly, repeat with a single dose in 3-4 weeks. Annual revaccination is recommended. A booster dose can be administered at more frequent intervals based upon individual horse or farm disease risk assessment or any time epidemic conditions exist or are reported. Consult your veterinarian.